Cell Therapy News/Articles, page-17074

What impact will this have on the revenues for Mesoblast? What impact might it have for the risk concerns of Mesoblasts's creditors?


No impact whatsoever according to you previously ?


Oh wait ... today it's now a big risk for Mesoblast and our Creditors but previously when you wanted to down play the Takeda license deal you claimed "Takeda revenues relatively anaemic" .... so Mr Flip Flop - which is it ?


https://hotcopper.com.au/threads/an...ults-webcast.7398592/page-32?post_id=67956046

Takeda revenues relatively anaemic.


It's hilarious to watch some on here claim one thing when it supports their narrative at the time but to then totally change tact when they want the FUD narrative to work in reverse ? Why would it be a risk concern for Oaktree if the Takeda revenues are so anemic .... according to you anyway ?


What is does do though is pave the way for Takeda to look at licensing Remestemcel-L if the latest trials replicate the earlier findings from the Remestemcel-L UC and Crohn's trials - these trial results are due to readout this quarter but hey do try and go off on a tangent about the Osiris trials from decades ago (yet again) if it makes you feel better


https://clinicaltrials.gov/study/NCT04548583?intr=Remestemcel-L&rank=1

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis


https://clinicaltrials.gov/study/NCT04543994?intr=Remestemcel-L&rank=2

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)